1-1 of 1
Neil A. Came
Close
Sort by
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data